Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin).

Abstract	Forty-five patients with pityriasis rubra pilaris were treated with oral 13-cis-retinoic acid (isotretinoin). There was marked improvement in the degree of erythema, in duration, and scaling noted within 4 weeks. Remission or maintained improvement persisted after stopping therapy in many of the patients. The drug is a significant addition to the therapeutic armamentarium in this difficult-to-treat disease.
Authors	L A Goldsmith, A E Weinrich, J Shupack
Journal	Journal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 6 Issue 4 Pt 2 Suppl Pg. 710-5 (Apr 1982) ISSN: 0190-9622 [Print] United States
PMID	7040513 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References	Tretinoin Isotretinoin
Topics	Adolescent Adult Aged Child Child, Preschool Clinical Trials as Topic Female Humans Infant Isomerism Isotretinoin Male Middle Aged Pityriasis Rubra Pilaris (diagnosis, drug therapy) Tretinoin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!